
|Articles|March 1, 2004
- Volume 0 0
Xenical
Advertisement
Roche (Nutley, NJ) recently announcedthat the FDA has approved labeling foruse of the prescription weight-loss medicationXenical (orlistat) in the managementof obese adolescents aged 12 to 16years. This approval offers physicians andparents of overweight and obese adolescentsa safe and effective treatment optionto help manage their weight. Xenicalworks locally in the stomach to preventdietary fat absorption by approximately30%. It helps the patient lose weight aswell as maintain the weight loss. For moreinformation, visit www.xenical.com.
Articles in this issue
over 22 years ago
Interface Speeds Up Prescription Fillingover 22 years ago
New Technologies Top Surveyover 22 years ago
Partnership Addresses Packaging Solutionsover 22 years ago
PDX Software Gets High Marksover 22 years ago
Polar Powder Cold Pak with Magnetic Therapyover 22 years ago
Seal•ONover 22 years ago
SaltAire Sinus Reliefover 22 years ago
Zim's Crack Creme Hand Sanitizerover 22 years ago
CoroWise Plant Sterolsover 22 years ago
CulturelleAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says
3
Brain Inflammation May Not Drive Persistent Long COVID Symptoms, New Imaging Study Finds
4
ADA 2026: Semaglutide Add-On Reduces Glycemic Burden, Cardiometabolic Risk in Older Adults With T2D
5





































































































































